RxDoctor Payments Data

Anthony Mattox, DO

Critical Care Medicine · Memphis, TNNPI 1558781492

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (28.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Intuitive Surgical at 60.0% of the total. 2025 is the largest year on record at $11,635, more than ten times the $660 reported in 2019. Among critical care medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,154in general payments, 2019–2025

Across 344 payments — averaging $96.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$20K
  • Genentech USA, Inc.$5K
  • AstraZeneca$2K
  • Sanofi$2K
  • GSK$741
  • Boston Scientific$644
  • plus $3K from 28 others

What the payments were for

  • Consulting fees$5,83518%
  • Speaking & faculty fees$7,50023%
  • Travel & lodging$9,45229%
  • Food & beverage$7,35522%
  • Education$3,0129%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,154 in reported general payments places this provider in the 95th percentile of 141 critical care medicine providers in Tennessee.

See all critical care medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$167,241
Medicare patients
676
Services billed
2,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate43$525,999
ArikayceAmikacin Liposomal/Neb.Accessr11$156,413
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$78,010
TezspireTezepelumab-Ekko13$58,923
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$30,634
Breo ElliptaFluticasone/Vilanterol34$19,525
Spiriva HandihalerTiotropium Bromide24$16,152
Spiriva RespimatTiotropium Bromide24$14,219
EliquisApixaban14$8,184
Incruse ElliptaUmeclidinium Bromide23$7,979
Combivent RespimatIpratropium/Albuterol Sulfate14$6,762
Arnuity ElliptaFluticasone Furoate16$4,873
SymbicortBudesonide/Formoterol Fumarate13$4,443
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$3,834
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$258$546,98081 claims
Insmed, Inc.Arikayce$185$156,41311 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$741$110,387173 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$1,904$94,00066 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 141 critical care medicine providers in Tennessee.

Other critical care medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →